Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect

Clinical and Applied Thrombosis/Hemostasis

Volumn 23, Issue 6, 2017, Pages 677-684

  Nagakari, Kunihiko ^a   Emmi, Mari ^b   Iba, Toshiaki ^c  

^a JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^b Kyowa Medex Co Ltd   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

antifactor Xa activity; apixaban; edoxaban; prothrombin time; rivaroxaban

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; APIXABAN; BLOOD CLOTTING FACTOR 10; CALCIUM; EDOXABAN; PROTHROMBIN COMPLEX; RIVAROXABAN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTICOAGULATION; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING TIME; HUMAN; HUMAN TISSUE; MONITORING; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; REVERSAL POTENTIAL; BLOOD CLOTTING; DRUG EFFECT; DRUG MONITORING; PROCEDURES;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DRUG MONITORING; HUMANS; PROTHROMBIN TIME; PYRAZOLES; PYRIDINES; PYRIDONES; RIVAROXABAN; THIAZOLES;

EID: 85027550243     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616638506     Document Type: Article

References (30)

1. Bauer KA,. Targeted anti-anticoagulants. N Engl J Med. 2015; 373 (6): 569-571.
2. Ray B, Keyrouz SG,. Management of anticoagulant-related intracranial hemorrhage: an evidence-based review. Crit Care. 2014; 18 (3): 223.
3. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M,. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011; 32 (3): 267-271.
4. Samama MM, Amiral J, Guinet C, Le Flem L, Seghatchian J,. Monitoring plasma levels of factor Xa inhibitors: how, why and when? Expert Rev Hematol. 2013; 6 (2): 155-164.
5. Tripodi A,. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. J Thromb Haemost. 2013; 11 (4): 576-578.
6. Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW,. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost. 2014; 12 (11): 1810-1815.
7. Hemphill JC III, Greenberg SM, Anderson CS, et al.American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015; 46 (7): 2032-2060.
8. Turecek PL, Váradi K, Gritsch H, Schwarz HP,. FEIBA: mode of action. Haemophilia. 2004; 10 (suppl 2): 3-9.
9. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013; 128 (11): 1234-1243.
10. Beyer-Westendorf J, Gehrisch S,. Phamacokinetics of rivaroxaban in adolescents. Hamostaseologie. 2014; 34 (1): 85-87.
11. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008; 100 (3): 453-461.
12. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010; 50 (7): 743-753.
13. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F,. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013; 110 (2): 283-294.
14. Kanemoto M, Kuhara H, Ueda T, et al. Association of apixaban therapy and prothrombin time in patients with atrial fibrillation. Circ J. 2014; 78 (11): 2651-2656.
15. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013; 76 (5): 776-786.
16. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365 (10): 883-891.
17. Granger CB, Alexander JH, McMurray JJ, et al.ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981-992.
18. Giugliano RP, Ruff CT, Braunwald E, et al.ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369 (22): 2093-2104.
19. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385 (9984): 2288-2295.
20. Yin OQ, Miller R,. Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers. Clin Drug Investig. 2014; 34 (10): 743-752.
21. Crowther M, Crowther MA,. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol. 2015; 35 (8): 1736-1745.
22. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015; 373 (25): 2413-2424.
23. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371 (22): 2141-2142.
24. Pernod G, Albaladejo P, Godier A, et al.Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis. 2013; 106 (6-7): 382-393.
25. Dager WE, Gosselin RC, Roberts AJ,. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013; 41 (5): e42-e46.
26. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124 (14): 1573-1579.
27. Lazo-Langner A, Lang ES, Douketis J,. Clinical review: clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care. 2013; 17 (3): 230.
28. Cuker A, Husseinzadeh H,. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015; 39 (3): 288-294.
29. Morishima Y, Kamisato C,. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol. 2015; 143 (2): 241-247.
30. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S,. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012; 129 (4): e77-e82.